India Takes a Genomic Leap: CSIR-IGIB and Serum Institute Partner to Deliver Indigenous Gene

India is stepping into a new era of genomic innovation, and at the heart of this transformation is a powerful collaboration between two scientific giants CSIR–Institute of Genomics and Integrative Biology (CSIR-IGIB) and the Serum Institute of India Pvt. Ltd. (SIIPL). Their partnership marks a defining moment in the country’s pursuit of accessible, high-precision gene therapies.

The collaboration centers on enFnCas9, an engineered high-fidelity CRISPR-Cas9 platform developed by IGIB. This indigenous technology, admired for its accuracy and efficiency, has the potential to reshape how India confronts complex genetic diseases. Among its most urgent applications is sickle cell disease, a debilitating condition that disproportionately affects tribal communities in central and eastern India. F